{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:51:48Z","timestamp":1767901908511,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40262-025-01563-8","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:31:23Z","timestamp":1762788683000},"page":"119-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Population Pharmacokinetic and Exposure\u2013Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis"],"prefix":"10.1007","volume":"65","author":[{"given":"Rodney L.","family":"Decker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"C. Steven","family":"Ernest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-6805","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdin.2020.10.002","volume":"2","author":"K Urban","year":"2021","unstructured":"Urban K, Chu S, Giesey RL, et al. The global, regional, and national burden of atopic dermatitis in 195 countries and territories: an ecological study from the Global Burden of Disease Study 2017. JAAD Int. 2021;2:12\u20138.","journal-title":"JAAD Int"},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298\u2013307.","journal-title":"J Immunol"},{"key":"1563_CR3","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. Jak-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260.","journal-title":"Front Immunol"},{"key":"1563_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9111575","author":"G Radi","year":"2021","unstructured":"Radi G, Simonetti O, Rizzetto G, et al. Baricitinib: the first Jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare. 2021. https:\/\/doi.org\/10.3390\/healthcare9111575.","journal-title":"Healthcare"},{"key":"1563_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1080\/09546634.2020.1839008","volume":"33","author":"K Reich","year":"2022","unstructured":"Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022;33:1521\u201330.","journal-title":"J Dermatolog Treat"},{"key":"1563_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"1563_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","volume":"157","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157:691\u20139.","journal-title":"JAMA Dermatol"},{"key":"1563_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjd.21630","volume":"187","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187:338\u201352.","journal-title":"Br J Dermatol"},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1563_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189:23\u201332.","journal-title":"Br J Dermatol"},{"key":"1563_CR11","unstructured":"European Commission Public Health - Union of Register of medicinal products. In. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed Sep 25, 2023."},{"key":"1563_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54:1354\u201361.","journal-title":"J Clin Pharmacol"},{"key":"1563_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/psp4.12251","volume":"6","author":"X Zhang","year":"2017","unstructured":"Zhang X, Chua L, Ernest C 2nd, et al. Dose\/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis. CPT Pharmacometrics Syst Pharmacol. 2017;6:804\u201313.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/bjc.2017.186","volume":"117","author":"SB Love","year":"2017","unstructured":"Love SB, Brown S, Weir CJ, et al. Embracing model-based designs for dose-finding trials. Br J Cancer. 2017;117:332\u20139.","journal-title":"Br J Cancer"},{"key":"1563_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/psp4.12385","volume":"8","author":"Q Wu","year":"2019","unstructured":"Wu Q, Peters SA. A retrospective evaluation of allometry, population pharmacokinetics, and physiologically-based pharmacokinetics for pediatric dosing using clearance as a surrogate. CPT Pharmacometrics Syst Pharmacol. 2019;8:220\u20139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1563_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.1310","volume":"59","author":"I Mahmood","year":"2019","unstructured":"Mahmood I, Tegenge MA. A comparative study between allometric scaling and physiologically based pharmacokinetic modeling for the prediction of drug clearance from neonates to adolescents. J Clin Pharmacol. 2019;59:189\u201397.","journal-title":"J Clin Pharmacol"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. The validated investigator global assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83:839\u201346.","journal-title":"J Am Acad Dermatol"},{"key":"1563_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4155\/bio-2023-0044","volume":"15","author":"ER Wickremsinhe","year":"2023","unstructured":"Wickremsinhe ER, Decker RL, Lee LB, et al. Microsampling in pediatric studies: pharmacokinetic sampling for baricitinib (Olumiant\u2122) in global pediatric studies. Bioanalysis. 2023;15:621\u201336.","journal-title":"Bioanalysis"},{"key":"1563_CR19","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102:2941\u201352.","journal-title":"J Pharm Sci"},{"key":"1563_CR20","unstructured":"Prevention CfDCa. Data Table of Weight-for-age Charts. In, Vol. 2023. https:\/\/www.cdc.gov\/growthcharts\/html_charts\/wtage.htm#males."},{"key":"1563_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2013a perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"1563_CR22","unstructured":"ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. In, Vol. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf."},{"key":"1563_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jcph.1360","volume":"59","author":"VS Purohit","year":"2019","unstructured":"Purohit VS, Ports WC, Wang C, Riley S. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. J Clin Pharmacol. 2019;59:811\u201320.","journal-title":"J Clin Pharmacol"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/psp4.13131","volume":"13","author":"RL Decker","year":"2024","unstructured":"Decker RL, Steven Ernest C 2nd, Radtke DB, et al. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis. CPT Pharmacometrics Syst Pharmacol. 2024;13:970\u201381.","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01563-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:30:56Z","timestamp":1767886256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01563-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company under license from Incyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.B. Radtke, A. Prakash, and X. Zhang are employees and shareholders of Eli Lilly and Company. R.L. Decker is a former employee of Eli Lilly and Company. C.S. Ernest II is a former employee of Eli Lilly and Company and currently employed with Metrum Research Group.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has received first regulatory authorization and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The protocol was approved by institutional review boards or ethics committees from all participating sites according to local requirements and was conducted according to International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent, or assent when appropriate, was provided for participation in the study and prior to any study-specific procedures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"R.L.D., C.S.E., A.P., and X.Z. wrote the manuscript; R.L.D., C.S.E., A.P., and X.Z. designed the research; R.L.D., C.S.E., D.B.R., and A.P. performed the research; R.L.D., C.S.E., D.B.R., and X.Z. analyzed the data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}